All In Biotech

Drug Trial Radar · NCT06577935

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Safety, Tolerability and Efficacy of AGA2118 in Postmenopausal Women With Low Bone Mineral Density

Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 379 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

379

Actual

Start

Oct 31, 2024

Primary completion

Dec 2026

Study completion Mar 2028

Sponsor

Lead sponsor
Angitia BiopharmaceuticalsIndustry
Sponsor type
Industry
First posted
Aug 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 55 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the effect of treatment with AGA2118 versus placebo at Month 12 on lumbar spine bone mineral density (BMD) in postmenopausal women with low bone mass.

Conditions

  • Postmenopausal Osteoporosis

Interventions

  • AGA2118Drug

    Subcutaneous injection

  • PlaceboOther

    Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from Baseline to Month 12 in lumbar spine bone mineral densityTime frame: 12 months

Locations

23 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Center for Advanced Research & Education

    Gainesville, Georgia

  • NM Clinical Research & Osteoporosis Center, Inc.

    Albuquerque, New Mexico

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania

  • Puget Sound Osteoporosis Center

    Burien, Washington

  • CIDIIM

    Córdoba, Argentina

  • Centro de Investigaciones Medicas Mar del Plata CIM

    Mar del Plata, Argentina

  • Centro Médico Dra Laura Maffei e Investigación Cliínica Aplicada

    Buenos Aires, Argentina, Argentina

  • Consultorio de Investigacion Clinica EMO SRL

    Buenos Aires, Argentina, Argentina

  • IDIM

    Buenos Aires, Argentina, Argentina

  • Investigaciones Reumatologicas y Osteologicas SRL

    Buenos Aires, Argentina, Argentina

  • Mautalen - Salud e Investigacion (Expertia S.A.)

    Buenos Aires, Argentina, Argentina

  • Stat Research

    Buenos Aires, Argentina, Argentina

  • Instituto Médico Strusberg

    Córdoba, Argentina, Argentina

  • Futuremeds Gdynia

    Gdynia, Poland

  • Krakowskie Centrum Medyczne

    Krakow, Poland

  • Futuremeds Lodz

    Lodz, Poland

  • Futuremeds Warszawa Centrum

    Warsaw, Poland

  • Futuremeds Targowek

    Warsaw, Poland

  • Futuremeds Wroclaw

    Wroclaw, Poland

  • CE "Hospital #1" of Zhytomyr City Council

    Kyiv, Ukraine, Ukraine

  • Medical Center Universal Clinic "Oberig" of "Kapytal" LCC

    Kyiv, Ukraine, Ukraine

  • PSSE Medical Centre Pulse

    Vinnytsia, Ukraine, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.